Jones Louise K, Saha Vaskar
Cancer Research UK Children's Cancer Group, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Br J Haematol. 2005 Aug;130(4):489-500. doi: 10.1111/j.1365-2141.2005.05611.x.
On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment. A few respond quickly to treatment and achieve long-term remission. Some fail to achieve remission after induction and the majority respond slowly to treatment. Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT). The use of imatinib along with conventional cytoreductive therapy, prior to allo-SCT appears to be the most promising strategy. The future lies in the molecular evaluation of response to treatment and combination targeted chemotherapy.
在目前的化疗方案下，费城染色体阳性的急性淋巴细胞白血病患儿对治疗的反应存在异质性。少数患儿对治疗反应迅速并实现长期缓解。一些患儿诱导治疗后未达到缓解，大多数患儿对治疗反应缓慢。治疗期间复发很常见，只有一部分病例在异基因干细胞移植（allo-SCT）后才维持缓解。在allo-SCT之前，将伊马替尼与传统的细胞减灭疗法联合使用似乎是最有前景的策略。未来在于对治疗反应的分子评估和联合靶向化疗。
